Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)
<b>Background:</b> Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | International Journal of Environmental Research and Public Health |
Subjects: | |
Online Access: | https://www.mdpi.com/1660-4601/18/5/2244 |
id |
doaj-980c74fa5eb44428b5870fe0535a7f6a |
---|---|
record_format |
Article |
spelling |
doaj-980c74fa5eb44428b5870fe0535a7f6a2021-02-25T00:04:22ZengMDPI AGInternational Journal of Environmental Research and Public Health1661-78271660-46012021-02-01182244224410.3390/ijerph18052244Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study)M. Rosa Dalmau Llorca0Carina Aguilar Martín1Noèlia Carrasco-Querol2Zojaina Hernández Rojas3Emma Forcadell Drago4Dolores Rodríguez Cumplido5Josep M. Pepió Vilaubí6Elisabet Castro Blanco7Alessandra Q. Gonçalves8José Fernández-Sáez9Equip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainGAVINA Research Group, 43500 Tortosa, SpainGAVINA Research Group, 43500 Tortosa, SpainEquip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainEquip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainGAVINA Research Group, 43500 Tortosa, SpainEquip d’Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, SpainGrupo GAVINA, Campus Terres de l’Ebre, Universitat Rovira i Virgili, 43500 Tortosa, Tarragona, SpainGAVINA Research Group, 43500 Tortosa, SpainGrupo GAVINA, Campus Terres de l’Ebre, Universitat Rovira i Virgili, 43500 Tortosa, Tarragona, Spain<b>Background:</b> Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. <strong>Methods:</strong> Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. <strong>Results</strong>: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). <strong>Conclusions:</strong> Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety.https://www.mdpi.com/1660-4601/18/5/2244atrial fibrillationdirect oral anticoagulantsrenal functiontime in therapeutic rangevitamin K antagonists |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
M. Rosa Dalmau Llorca Carina Aguilar Martín Noèlia Carrasco-Querol Zojaina Hernández Rojas Emma Forcadell Drago Dolores Rodríguez Cumplido Josep M. Pepió Vilaubí Elisabet Castro Blanco Alessandra Q. Gonçalves José Fernández-Sáez |
spellingShingle |
M. Rosa Dalmau Llorca Carina Aguilar Martín Noèlia Carrasco-Querol Zojaina Hernández Rojas Emma Forcadell Drago Dolores Rodríguez Cumplido Josep M. Pepió Vilaubí Elisabet Castro Blanco Alessandra Q. Gonçalves José Fernández-Sáez Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study) International Journal of Environmental Research and Public Health atrial fibrillation direct oral anticoagulants renal function time in therapeutic range vitamin K antagonists |
author_facet |
M. Rosa Dalmau Llorca Carina Aguilar Martín Noèlia Carrasco-Querol Zojaina Hernández Rojas Emma Forcadell Drago Dolores Rodríguez Cumplido Josep M. Pepió Vilaubí Elisabet Castro Blanco Alessandra Q. Gonçalves José Fernández-Sáez |
author_sort |
M. Rosa Dalmau Llorca |
title |
Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study) |
title_short |
Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study) |
title_full |
Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study) |
title_fullStr |
Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study) |
title_full_unstemmed |
Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study) |
title_sort |
oral anticoagulant adequacy in non-valvular atrial fibrillation in primary care: a cross-sectional study using real-world data (fantas-tic study) |
publisher |
MDPI AG |
series |
International Journal of Environmental Research and Public Health |
issn |
1661-7827 1660-4601 |
publishDate |
2021-02-01 |
description |
<b>Background:</b> Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. <strong>Methods:</strong> Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. <strong>Results</strong>: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). <strong>Conclusions:</strong> Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety. |
topic |
atrial fibrillation direct oral anticoagulants renal function time in therapeutic range vitamin K antagonists |
url |
https://www.mdpi.com/1660-4601/18/5/2244 |
work_keys_str_mv |
AT mrosadalmaullorca oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT carinaaguilarmartin oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT noeliacarrascoquerol oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT zojainahernandezrojas oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT emmaforcadelldrago oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT doloresrodriguezcumplido oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT josepmpepiovilaubi oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT elisabetcastroblanco oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT alessandraqgoncalves oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy AT josefernandezsaez oralanticoagulantadequacyinnonvalvularatrialfibrillationinprimarycareacrosssectionalstudyusingrealworlddatafantasticstudy |
_version_ |
1724252316770500608 |